ClinicalTrials.gov
ClinicalTrials.gov Menu

Study to Compare PT007 to Placebo MDI and Open-Label Proventil® HFA in Adult and Adolescent Subjects With Asthma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03364608
Recruitment Status : Completed
First Posted : December 6, 2017
Last Update Posted : April 5, 2018
Sponsor:
Information provided by (Responsible Party):
AstraZeneca

December 1, 2017
December 6, 2017
April 5, 2018
December 15, 2017
March 30, 2018   (Final data collection date for primary outcome measure)
Change from baseline in FEV1 AUC0-6 [ Time Frame: 1 Day ]
Same as current
Complete list of historical versions of study NCT03364608 on ClinicalTrials.gov Archive Site
  • Change from baseline in FEV1 AUC0-4 [ Time Frame: 1 Day ]
  • Peak change from baseline in FEV1 [ Time Frame: 1 Day ]
Same as current
Not Provided
Not Provided
 
Study to Compare PT007 to Placebo MDI and Open-Label Proventil® HFA in Adult and Adolescent Subjects With Asthma
A Randomized, Double-blind, Single Dose, Placebo-controlled, 5-Period, 5-Treatment, Crossover, Multi-center, Dose-ranging Study to Compare PT007 to Placebo MDI and Open-Label Proventil® HFA in Adult and Adolescent Subjects With Mild to Moderate Asthma
This is a randomized, double-blind, single-dose, placebo-controlled, 5-period, 5-treatment, crossover, multi-center study to assess the bronchodilatory effect and safety of 2 dose levels of Albuterol Sulfate Pressurized Inhalation Suspension (hereafter referred to as AS MDI), 90 μg and 180 μg, compared with placebo for AS MDI (hereafter referred to as Placebo MDI) and open-label Proventil® hydrofluoroalkane (HFA; hereafter referred to as Proventil) 90 μg and 180 μg in adult and adolescent subjects with mild to moderate asthma. This study design utilizes 10 treatment sequences.
This is a 5-period crossover study. Each Treatment Period is 1 day. Subjects will receive a single dose of randomized study drug at each of the 5 Treatment Visits (Visits 2, 3, 4, 5, and 6), with a 3- to 7-day Washout Period between Treatment Visits.
Interventional
Phase 2
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Asthma
  • Drug: AS MDI 90 μg
    AS MDI 90 μg (2 actuations of 45 μg/actuation)
    Other Name: AS MDI
  • Drug: AS MDI 180 µg
    AS MDI 180 μg (2 actuations of 90 μg/actuation)
    Other Name: AS MDI
  • Other: Placebo MDI
    Placebo MDI (2 actuations)
  • Drug: Proventil 90 μg
    Proventil 90 μg (1 actuation of 90 μg/actuation)
    Other Name: Proventil
  • Drug: Proventil 180 μg
    Proventil 180 μg (2 actuations of 90 μg/actuation)
    Other Name: Proventil
  • Experimental: • AS MDI 90 µg
    (2 actuations of 45 µg/actuation)
    Intervention: Drug: AS MDI 90 μg
  • Experimental: • AS MDI 180 µg
    (2 actuations of 90 µg/actuation)
    Intervention: Drug: AS MDI 180 µg
  • Placebo Comparator: • Placebo MDI
    (2 actuations)
    Intervention: Other: Placebo MDI
  • Active Comparator: • Proventil 90 µg
    (1 actuation of 90 µg/actuation)
    Intervention: Drug: Proventil 90 μg
  • Active Comparator: • Proventil 180 µg
    (2 actuations of 90 µg/actuation)
    Intervention: Drug: Proventil 180 μg
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
86
70
March 30, 2018
March 30, 2018   (Final data collection date for primary outcome measure)

Inclusion Criteria

  • Are at least 12 years of age and no older than 65 years
  • Have stable (for 6 months) physician-diagnosed asthma with historical documentation of the diagnosis
  • Must be receiving 1 of the following required inhaled asthma therapies listed below for at least the last 30 days; Only SABA, which is used as needed for rescue, or Low to medium doses of ICS (alone or in combination with LABA), used regularly as maintenance asthma therapy
  • Demonstrate acceptable spirometry performance (ie, meet American Thoracic Society [ATS]/European Respiratory Society [ERS] acceptability/repeatability criteria
  • Pre-bronchodilator FEV1 of ≥40 to <90% predicted normal value after withholding SABA for ≥6 hours
  • Confirmed FEV1 reversibility to Ventolin, defined as a post-Ventolin increase in FEV1 of ≥15%
  • only 2 reversibility testing attempts are allowed

Exclusion Criteria:

  • Chronic obstructive pulmonary disease or other significant lung disease (eg, chronic bronchitis, emphysema, bronchiectasis with the need of treatment, cystic fibrosis, or bronchopulmonary dysplasia)
  • Oral corticosteroid use (any dose) within 6 weeks
  • Current smokers, former smokers with >10 pack-years history, or former smokers who stopped smoking <6 months (including all forms of tobacco, e-cigarettes [vaping], and marijuana)
  • Life-threatening asthma as defined as any history of significant asthma episode(s) requiring intubation associated with hypercapnia, respiratory arrest, hypoxic seizures, or asthma-related syncopal episode(s)
  • Historical or current evidence of a clinically significant disease
  • Cancer not in complete remission for at least 5 years
  • Hospitalized for psychiatric disorder or attempted suicide within 1 year
  • Unable to abstain from protocol-defined prohibited medications during the study
Sexes Eligible for Study: All
12 Years to 65 Years   (Child, Adult)
No
Contact information is only displayed when the study is recruiting subjects
United States
 
 
NCT03364608
D6930C00001
Yes
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: Yes
Not Provided
AstraZeneca
AstraZeneca
Not Provided
Not Provided
AstraZeneca
April 2018

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP